Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center

Leuk Lymphoma. 2018 Apr;59(4):1019-1021. doi: 10.1080/10428194.2017.1349906. Epub 2017 Jul 21.

Authors

Affiliations

¹ a Hospital del Mar, Hematology, Passeig Maritim 25-29 , Barcelona , Spain.
² b Institut Municicpla d'investigació Mèdica (Imim) , Barcelona , Spain.

PMID: 28728440
DOI: 10.1080/10428194.2017.1349906

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Humans
Injection Site Reaction / epidemiology*
Injection Site Reaction / etiology
Injections, Subcutaneous / adverse effects
Lymphoma, B-Cell / drug therapy*
Male
Middle Aged
Rituximab / administration & dosage
Rituximab / adverse effects*
Rituximab / therapeutic use
Treatment Outcome

Substances

Rituximab